Why the study?
The mechanisms underlying ischemia-reperfusion injury after reperfusion treatment for myocardial infarction are incompletely understood and effective pharmacological interventions are limited.
Does disulfiram reduce cardiomyocyte death and improve heart function after ischemic injury in preclinical models?
Does disulfiram reduce cardiomyocyte death and improve heart function after ischemic injury in preclinical models?
Disulfiram shows potential as a cardioprotective agent against ischemia-reperfusion injury by inhibiting Gasdermin D.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for disulfiram in ischemia-reperfusion injury; prospective human trials needed before clinical consideration.
Ischemia–reperfusion injury occurs after reperfusion treatment for patients suffering myocardial infarction, however the underlying mechanisms are incompletely understood and effective pharmacological interventions are limited. Here, we report the identification and characterization of the FDA-approved drug disulfiram (DSF) as a cardioprotective compound. By applying high-throughput chemical screening, we found that DSF decreased H 2 O 2 -induced cardiomyocyte death by inhibiting Gasdermin D, but not ALDH1, in cardiomyocytes. Oral gavage of DSF decreased myocardial infarct size and improved heart function after myocardial ischemia–reperfusion injury in rats. Therefore, this work reveals DSF as a potential therapeutic compound for the treatment of ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: